A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

Abstract

Virus neutralization remains the gold standard for determining antibody efficacy. Therefore, a high-throughput assay to measure SARS-CoV-2 neutralizing antibodies is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, and vaccine development. Here, we report on a fluorescence-based SARS-CoV-2 neutralization assay that detects SARS-CoV-2 neutralizing antibodies in COVID-19 patient specimens and yields comparable results to plaque reduction neutralizing assay, the gold standard of serological testing. The fluorescence-based neutralization assay is specific to measure COVID-19 neutralizing antibodies without cross reacting with patient specimens with other viral, bacterial, or parasitic infections. Collectively, our approach offers a rapid platform that can be scaled to screen people for antibody protection from COVID-19, a key parameter necessary to safely reopen local communities.

References 18

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.
   A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020

   No notice
5. 5.
   Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2 · 2020

   No notice
6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.
   Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients · 2020

   No notice
10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.
    Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020 · 2020

    No notice
12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.
    An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment · 2020

    No notice
14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.
    A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity · 2020

    No notice
16. 16.
    A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 · 2020

    Corrected
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 5

• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models · 2022
  No notice
• Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera · 2021
  Not checked
• Evaluation of the humoral response induced by BBIBP-CorV vaccine by determining neutralizing antibodies in peruvian healthcare personnel · 2021
  Not checked
• Using alt text to make science Twitter more accessible for people with visual impairments · 2020
  Not checked
• Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT) · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.